Biogen (NASDAQ: BIIB) reported Q1 EPS of $5.34, $0.30 better than the analyst estimate of $5.04. Revenue for the quarter came in at $2.69 billion versus the consensus estimate of $2.65 billion.

GUIDANCE:

Biogen sees FY2021 EPS of $17.50-$19.00, versus the consensus of $18.41. Biogen sees FY2021 revenue of $10.45-10.75 billion, versus the consensus of $10.57 billion.

For earnings history and earnings-related data on Biogen (BIIB) click here.